Fast Field Cycling Imaging of Kidney Disease

Kidney Diseases Clinical Trial

Official title:

Investigating a Novel Molecular Imaging Technique, Fast Field-Cycling, for Kidney Health and Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05851417
• Other study ID #: 2-095-21
• Status: Recruiting
• Phase: N/A
• Start date: March 8, 2023
• Est. completion date: September 2023

Study information

• Verified date: May 2023
• Source: University of Aberdeen
• Contact: Celia G Alvarez Campano, Dr
• Phone: +441224437828
• Email: celia.alvarezcampano[@]abdn.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this pilot study is to explore the utility of Fast Field-Cycling (FFC) imaging in monitoring kidney disease. The main questions it aims to answer are: - If FFC imaging can differentiate healthy kidney from kidney disease - If there is an association between FFC imaging and standard clinical tests Participants will provide one blood and on urine sample, and will have one FFC imaging scan.

Description:

The kidneys are vital organs responsible for clearance of toxins in the human body. The kidneys age over time and this ageing process is complex, involving changes both to their structure and function, and can be accelerated by disease processes. Without an invasive biopsy procedure, it is often difficult to distinguish between age-related damage from active disease, that could be modified with treatment. Even with a biopsy, certain diseases are often patchy and can be overlooked if missed by the biopsy sample procedure. Alternative imaging approaches have limited ability to differentiate between modifiable and non-modifiable disease processes. The investigators, based at the University of Aberdeen, have developed a unique magnetic imaging technology, Fast Field-Cycling (FFC) imaging. FFC derives from conventional MRI scanners but has the ability to change its magnetic field strength during a scan. This is equivalent to having many MRI scanners in one device and allows completely new analyses of the behaviour of tissue remodelling to pathological processes, from millimetres to nanometres. This information is invisible to standard MRI scanners and several pilot studies have shown great potential for FFC in cancer and stroke. This pilot study aims to investigate if FFC can detect changes in kidney microstructure. If FFC imaging shows that it is effective in monitoring kidney disease, then this would contribute to evidence from previous studies promoting the need to develop a new scanner that could be used clinically in the future. The study will include 20 patients with kidney damage (native or transplant kidneys) and 10 live donors (healthy volunteers). Each participant (patients and live donors) will have urine and blood tests, along with an FFC-MRI scan. Data analyses will be performed using the appropriate statistical methods depending on the distribution of the variables extracted.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: September 2023
• Est. primary completion date: September 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

All participants:

• Participants must be aged 18 and above
• Participants who meet the safety criteria for undergoing an MRI scan.
• Participants who can pass through a 50 cm-diameter circular hoop to ensure they will be able to fit inside the scanner
• Participants must be able to give fully informed consent.
• Participants must be mobile enough to be positioned onto the FFC-MRI scanner couch.

Native kidney damage patients:

• Patients referred for a kidney biopsy and laboratory evidence (blood tests and urine abnormalities) of kidney impairment.
• Patients who are newly referred.

Transplant patients:

• Patients with functioning kidney transplant undergoing a kidney biopsy as a part of routine clinical care.
• Patients who are newly referred. Live donors
• Live kidney donors, patients investigated for potential kidney donation and deemed suitable for donation. Exclusion Criteria:

Native kidney Damage Patients:

• Patients with single native kidney.
• Patients on dialysis.

Transplant patients:

• Patients with non-functioning kidney transplant. Live donors
• Live donors who deemed unsuitable for kidney donation by the living kidney donation clinic.

All participants:

• MRI-incompatible conditions, as detected in the MRI safety screening sheet.
• Participants under 18 years old.
• Participants who are unable to give fully informed consent.
• Women who are pregnant.
• Restrictions to mobility that would prevent the correct positioning in the scanner.
• Participants who suffer from claustrophobia.
• Body mass index larger than 34, due to the limited bore size of the scanner.
• Participants who are unable to communicate in English.

Related Conditions & MeSH terms

• Kidney Diseases

Intervention

Device:
• Fast Field-Cycling (FFC) imaging
FFC scan

Locations

Country	Name	City	State
United Kingdom	NHS Grampian	Aberdeen

Sponsors (2)

Lead Sponsor	Collaborator
University of Aberdeen	NHS Grampian

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Kidney microstructure assessed by Fast Field Cycling (FFC) imaging scan	Evaluating the potential of FFC T1 dispersion profiles in the clinical assessment of kidney microstructure	At baseline